Blue Earth Diagnostics, Inc.
Ask us about innovation in PET imaging of cancer.
Blue Earth Diagnostics Inc. is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Blue Earth is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The Company’s first approved and commercially available product is Axumin® (fluciclovine F18), a novel molecular imaging agent for use in PET imaging to detect and localize prostate cancer in men experiencing biochemical recurrence. Blue Earth Diagnostics Inc. of Burlington, Mass., is the U.S. subsidiary of U.K.-based Blue Earth Diagnostics Ltd. The Company is funded by Syncona Limited, an investment company listed on the London Stock Exchange. For more information, visit: www.blueearthdx.com.
Brands: Axumin® (fluciclovine F 18) injection